HRP20210692T1 - Oblici soli (s)-kinuklidin-3-il (2-(2-(4-fluorfenil)tiazol-4-il)propan-2-il)karbamata - Google Patents
Oblici soli (s)-kinuklidin-3-il (2-(2-(4-fluorfenil)tiazol-4-il)propan-2-il)karbamata Download PDFInfo
- Publication number
- HRP20210692T1 HRP20210692T1 HRP20210692TT HRP20210692T HRP20210692T1 HR P20210692 T1 HRP20210692 T1 HR P20210692T1 HR P20210692T T HRP20210692T T HR P20210692TT HR P20210692 T HRP20210692 T HR P20210692T HR P20210692 T1 HRP20210692 T1 HR P20210692T1
- Authority
- HR
- Croatia
- Prior art keywords
- crystalline form
- alpha
- use according
- disease
- lysosomal storage
- Prior art date
Links
- YFHRCLAKZBDRHN-MRXNPFEDSA-N [(3s)-1-azabicyclo[2.2.2]octan-3-yl] n-[2-[2-(4-fluorophenyl)-1,3-thiazol-4-yl]propan-2-yl]carbamate Chemical compound O([C@H]1C2CCN(CC2)C1)C(=O)NC(C)(C)C(N=1)=CSC=1C1=CC=C(F)C=C1 YFHRCLAKZBDRHN-MRXNPFEDSA-N 0.000 title claims 2
- 150000003839 salts Chemical group 0.000 title 1
- 208000015439 Lysosomal storage disease Diseases 0.000 claims 6
- 208000015872 Gaucher disease Diseases 0.000 claims 4
- 102000009133 Arylsulfatases Human genes 0.000 claims 3
- 208000024720 Fabry Disease Diseases 0.000 claims 3
- 102000004547 Glucosylceramidase Human genes 0.000 claims 3
- 108010017544 Glucosylceramidase Proteins 0.000 claims 3
- 102000005840 alpha-Galactosidase Human genes 0.000 claims 3
- 108010030291 alpha-Galactosidase Proteins 0.000 claims 3
- 229940049920 malate Drugs 0.000 claims 3
- 108060007951 sulfatase Proteins 0.000 claims 3
- -1 (S)-quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate malate Chemical class 0.000 claims 2
- 102000005327 Palmitoyl protein thioesterase Human genes 0.000 claims 2
- 108020002591 Palmitoyl protein thioesterase Proteins 0.000 claims 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 claims 2
- 238000002641 enzyme replacement therapy Methods 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 208000006515 AB Variant Tay-Sachs Disease Diseases 0.000 claims 1
- 102100031317 Alpha-N-acetylgalactosaminidase Human genes 0.000 claims 1
- 102100034561 Alpha-N-acetylglucosaminidase Human genes 0.000 claims 1
- 101710106740 Alpha-N-acetylglucosaminidase Proteins 0.000 claims 1
- 102000004092 Amidohydrolases Human genes 0.000 claims 1
- 108090000531 Amidohydrolases Proteins 0.000 claims 1
- 102100022440 Battenin Human genes 0.000 claims 1
- 102000004201 Ceramidases Human genes 0.000 claims 1
- 108090000751 Ceramidases Proteins 0.000 claims 1
- 102100034505 Ceroid-lipofuscinosis neuronal protein 5 Human genes 0.000 claims 1
- 102100034480 Ceroid-lipofuscinosis neuronal protein 6 Human genes 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 201000008892 GM1 Gangliosidosis Diseases 0.000 claims 1
- 208000037310 Gaucher disease type 2 Diseases 0.000 claims 1
- 208000037311 Gaucher disease type 3 Diseases 0.000 claims 1
- 108010060309 Glucuronidase Proteins 0.000 claims 1
- 102000053187 Glucuronidase Human genes 0.000 claims 1
- 102000016871 Hexosaminidase A Human genes 0.000 claims 1
- 108010053317 Hexosaminidase A Proteins 0.000 claims 1
- 102000016870 Hexosaminidase B Human genes 0.000 claims 1
- 108010053345 Hexosaminidase B Proteins 0.000 claims 1
- 101000901683 Homo sapiens Battenin Proteins 0.000 claims 1
- 101000710208 Homo sapiens Ceroid-lipofuscinosis neuronal protein 5 Proteins 0.000 claims 1
- 101000710215 Homo sapiens Ceroid-lipofuscinosis neuronal protein 6 Proteins 0.000 claims 1
- 101001124388 Homo sapiens NPC intracellular cholesterol transporter 1 Proteins 0.000 claims 1
- 101001109579 Homo sapiens NPC intracellular cholesterol transporter 2 Proteins 0.000 claims 1
- 101000710213 Homo sapiens Protein CLN8 Proteins 0.000 claims 1
- 108010053927 Iduronate Sulfatase Proteins 0.000 claims 1
- 102000004627 Iduronidase Human genes 0.000 claims 1
- 108010003381 Iduronidase Proteins 0.000 claims 1
- 102000004882 Lipase Human genes 0.000 claims 1
- 108090001060 Lipase Proteins 0.000 claims 1
- YTTRPBWEMMPYSW-HRRFRDKFSA-N N(4)-(beta-N-acetyl-D-glucosaminyl)-L-asparagine Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1NC(=O)C[C@H]([NH3+])C([O-])=O YTTRPBWEMMPYSW-HRRFRDKFSA-N 0.000 claims 1
- 102100029565 NPC intracellular cholesterol transporter 1 Human genes 0.000 claims 1
- 102100022737 NPC intracellular cholesterol transporter 2 Human genes 0.000 claims 1
- 101000652829 Neosartorya fumigata (strain ATCC MYA-4609 / Af293 / CBS 101355 / FGSC A1100) Exo-alpha-sialidase Proteins 0.000 claims 1
- 102100034479 Protein CLN8 Human genes 0.000 claims 1
- 102000011971 Sphingomyelin Phosphodiesterase Human genes 0.000 claims 1
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 claims 1
- 108010039203 Tripeptidyl-Peptidase 1 Proteins 0.000 claims 1
- 102100034197 Tripeptidyl-peptidase 1 Human genes 0.000 claims 1
- 102100038413 UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase Human genes 0.000 claims 1
- 108010024501 UDPacetylglucosamine-dolichyl-phosphate acetylglucosamine-1-phosphate transferase Proteins 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- 102000005421 acetyltransferase Human genes 0.000 claims 1
- 108020002494 acetyltransferase Proteins 0.000 claims 1
- 102000016679 alpha-Glucosidases Human genes 0.000 claims 1
- 108010028144 alpha-Glucosidases Proteins 0.000 claims 1
- 102000012086 alpha-L-Fucosidase Human genes 0.000 claims 1
- 108010061314 alpha-L-Fucosidase Proteins 0.000 claims 1
- 102000019199 alpha-Mannosidase Human genes 0.000 claims 1
- 108010012864 alpha-Mannosidase Proteins 0.000 claims 1
- 108010015684 alpha-N-Acetylgalactosaminidase Proteins 0.000 claims 1
- 102000005936 beta-Galactosidase Human genes 0.000 claims 1
- 108010005774 beta-Galactosidase Proteins 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 108010089932 heparan sulfate sulfatase Proteins 0.000 claims 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (16)
1. Kristalni oblik A (S)-kinuklidin-3-il (2-(2-(4-fluorfenil)tiazol-4-il)propan-2-il)karbamat malata, naznačen time što navedena difrakcija rendgenskih zraka na prahu obuhvaća sljedeći 2-theta vrh izmjereno korištenjem CuKα zračenja: 18,095.
2. Kristalni oblik A (S)-kinuklidin-3-il (2-(2-(4-fluorfenil)tiazol-4-il)propan-2-il)karbamat malata prema patentnom zahtjevu 1, naznačen time što navedena difrakcija rendgenskih zraka na prahu obuhvaća sljedeće 2-theta vrhove izmjereno korištenjem CuKα zračenja:
18,095 i 17,493;
18,095 i 19,516;
18,095, 17,493, i 19,516;
18,095, 17,493, 19,516 i 20,088; ili
18,095, 17,493, 19,516, 20,088 i 17,125.
3. Kristalni oblik A (S)-kinuklidin-3-il (2-(2-(4-fluorfenil)tiazol-4-il)propan-2-il)karbamat malata prema patentnom zahtjevu 1 ili zahtjevu 2, naznačen time što ima difraktogram sa Slike 1.
4. Kristalni oblik prema bilo kojem od patentnih zahtjeva 1 do 3 naznačen time što se koristi u terapiji.
5. Kristalni oblik prema bilo kojem od patentnih zahtjeva 1 do 3 naznačen time što se koristi u liječenju lizosomske bolesti nakupljanja, bilo samostalno ili kao kombinirana terapija s nadomjesnom enzimskom terapijom.
6. Kristalni oblik za uporabu prema patentnom zahtjevu 5, naznačen time što je lizosomska bolest nakupljanja Gaucherova bolest, Fabryjeva bolest, GM1-gangliozidoza, nedostatak aktivatora GM2, Tay-Sachs ili Sandhoff.
7. Kristalni oblik za uporabu prema patentnom zahtjevu 6, naznačen time što je lizosomska bolest nakupljanja Gaucherova bolest.
8. Kristalni oblik za uporabu prema patentnom zahtjevu 6, naznačen time što je lizosomska bolest nakupljanja Fabryjeva bolest.
9. Kristalni oblik za uporabu prema bilo kojem od patentnih zahtjeva 5 do 8, naznačen time što je navedeni kristalni oblik za primjenu u dozi od 0,5 mg/kg do 300 mg/kg.
10. Kristalni oblik za uporabu prema bilo kojem od patentnih zahtjeva 5 do 8, naznačen time što je navedeni kristalni oblik za oralnu primjenu u dozi od dva puta dnevno od 50 mg do 100 mg.
11. Kristalni oblik za uporabu prema bilo kojem od patentnih zahtjeva 5 do 10, naznačen time što je navedeni kristalni oblik za upotrebu u kombinaciji s enzimom odabranim od glukocerebrozidaze, sfingomijelinaze, ceramidaze, GM1-gangliozid-beta-galaktozidaze, heksosaminidaze A, heksosaminidaze B, beta-galaktocerebrozidaze, alfa-L-iduronidaze, iduronat sulfataze, heparan-N-sulfataze, N-acetil-alfa-glukozaminidaze, acetil CoA:alfa-glukozaminid acetil-transferaze, N-acetil-alfa-glukozamine-6-sulfataze, galaktozamin-6-sulfataze, beta-galaktozidaze, galaktozamin-4-sulfataze (arilsulfataze B), beta-glukuronidaze, arilsulfataze A, arilsulfataze C, alfa-neuraminidaze, N-acetil-glukozamin-1-fosfat transferaze, alfa-galaktozidaze A, alfa-N-acetilgalaktozaminidaze, alfa-glukozidaze, alfa-fukozidaze, alfa-manozidaze, aspartilglukozamin amidaze, kisele lipaze, palmitoil-protein tioesteraze (CLN-1), PPT1, TPP1, CLN3, CLN5, CLN6, CLN8, NPC1 i NPC2.
12. Kristalni oblik za uporabu prema patentnom zahtjevu 5, naznačen time što je lizosomska bolest nakupljanja Gaucherova bolest tipa 2 ili tipa 3, i pri čemu je kristalni oblik za uporabu u kombinaciji s glukocerebrosidazom.
13. Kristalni oblik za uporabu prema patentnom zahtjevu 12, naznačen time što je glukocerebrosidaza za primjenu u režimu doziranja od 1 U/kg tri puta tjedno do 120 U/kg jednom svaka dva tjedna.
14. Kristalni oblik za uporabu prema patentnom zahtjevu 5, naznačen time što je lizosomska bolest nakupljanja Fabryjeva bolest, i pri čemu je kristalni oblik za uporabu u kombinaciji s alfa-galaktozidazom A.
15. Kristalni oblik za uporabu prema patentnom zahtjevu 14, naznačen time što je alfa-galaktozidaza A za primjenu u režimu doziranja od 0,1 do 100 mg/kg i.v. u učestalosti od svakog drugog dana do jednom tjedno ili svaka dva tjedna.
16. Kristalni oblik za uporabu prema bilo kojem od patentnih zahtjeva 5 do 15, naznačen time što je navedeni kristalni oblik za primjenu prije, istodobno ili nakon navedene enzimske nadomjesne terapije.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361791706P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/027081 WO2014152215A1 (en) | 2013-03-15 | 2014-03-14 | SALT FORMS OF (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate |
| EP14718854.4A EP2970250B1 (en) | 2013-03-15 | 2014-03-14 | Salt forms of (s)-quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210692T1 true HRP20210692T1 (hr) | 2021-06-11 |
Family
ID=50543351
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210692TT HRP20210692T1 (hr) | 2013-03-15 | 2021-05-04 | Oblici soli (s)-kinuklidin-3-il (2-(2-(4-fluorfenil)tiazol-4-il)propan-2-il)karbamata |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US9518049B2 (hr) |
| EP (1) | EP2970250B1 (hr) |
| JP (1) | JP6438455B2 (hr) |
| KR (1) | KR102302064B1 (hr) |
| CN (1) | CN105189490A (hr) |
| AR (1) | AR095435A1 (hr) |
| AU (1) | AU2014240028B2 (hr) |
| BR (1) | BR112015022907B1 (hr) |
| CA (1) | CA2906691A1 (hr) |
| CL (1) | CL2015002701A1 (hr) |
| DK (1) | DK2970250T3 (hr) |
| EA (1) | EA037527B1 (hr) |
| ES (1) | ES2872326T3 (hr) |
| HK (1) | HK1214821A1 (hr) |
| HR (1) | HRP20210692T1 (hr) |
| HU (1) | HUE054349T2 (hr) |
| IL (1) | IL241229B (hr) |
| JO (1) | JO3713B1 (hr) |
| LT (1) | LT2970250T (hr) |
| MA (1) | MA38488A1 (hr) |
| MX (1) | MX370178B (hr) |
| MY (1) | MY181766A (hr) |
| PH (1) | PH12015502021A1 (hr) |
| PL (1) | PL2970250T3 (hr) |
| PT (1) | PT2970250T (hr) |
| RS (1) | RS61852B1 (hr) |
| SA (1) | SA515361078B1 (hr) |
| SG (1) | SG11201507054YA (hr) |
| SI (1) | SI2970250T1 (hr) |
| TN (1) | TN2015000427A1 (hr) |
| TW (1) | TWI713438B (hr) |
| UY (1) | UY35439A (hr) |
| WO (1) | WO2014152215A1 (hr) |
| ZA (1) | ZA201506602B (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA37975B2 (fr) | 2012-09-11 | 2021-03-31 | Genzyme Corp | Inhibiteurs de synthase de glucosylcéramide |
| CA2931981C (en) * | 2013-12-11 | 2022-05-03 | Genzyme Corporation | Glucosylceramide synthase inhibitors |
| US10519157B2 (en) * | 2018-02-09 | 2019-12-31 | X-Cutag Therapeutics, Inc. | Deuterated compounds for treating Fabry, Gaucher, Parkinson's and related diseases and conditions, and compositions and methods thereof |
| WO2020163337A1 (en) | 2019-02-04 | 2020-08-13 | Genzyme Corporation | Treatment of ciliopathies using inhibitors of glucosylceramide synthase (gcs) |
| AU2021215396A1 (en) | 2020-02-03 | 2022-09-29 | Genzyme Corporation | Methods for treating neurological symptoms associated with lysosomal storage diseases |
| US11857512B2 (en) | 2020-07-24 | 2024-01-02 | Genzyme Corporation | Pharmaceutical compositions comprising venglustat |
| CN116322679A (zh) | 2020-07-30 | 2023-06-23 | 建新公司 | 用于降低脑组织中鞘糖脂浓度的方法以及涉及降低脑组织中鞘糖脂浓度的神经系统变性疾病的治疗方法 |
| WO2022215083A1 (en) * | 2021-04-05 | 2022-10-13 | Msn Laboratories Private Limited, R&D Center | Solid state forms of (s)-quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl) carbamate or salts and process for its preparation thereof |
| WO2024116127A1 (en) | 2022-12-01 | 2024-06-06 | Genzyme Corporation | Venglustat in combination with a strong or moderate inhibitor of cyp3a4 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5549892A (en) | 1988-12-23 | 1996-08-27 | Genzyme Corporation | Enhanced in vivo uptake of glucocerebrosidase |
| US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
| US5733761A (en) | 1991-11-05 | 1998-03-31 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| CA2305768A1 (en) | 1997-10-29 | 2000-02-24 | Genzyme Corporation | Compositions and methods for treating lysosomal storage disease |
| GB0400812D0 (en) | 2004-01-14 | 2004-02-18 | Celltech R&D Ltd | Novel compounds |
| JP2008519840A (ja) | 2004-11-10 | 2008-06-12 | ジェンザイム・コーポレイション | 糖尿病の処置方法 |
| WO2010091104A1 (en) | 2009-02-06 | 2010-08-12 | Exelixis, Inc. | Glucosylceramide synthase inhibitors |
| PL3482767T3 (pl) | 2009-08-28 | 2022-02-14 | Icahn School Of Medicine At Mount Sinai | Enzymatyczna terapia zastępcza ze zwiększaniem dawki do leczenia niedoboru kwaśnej sfingomielinazy |
| SI2685986T1 (sl) * | 2011-03-18 | 2020-03-31 | Genzyme Corporation | Inhibitor glukozilceramid sintaze |
-
2014
- 2014-03-11 JO JOP/2014/0088A patent/JO3713B1/ar active
- 2014-03-13 AR ARP140100981A patent/AR095435A1/es unknown
- 2014-03-14 BR BR112015022907-7A patent/BR112015022907B1/pt active IP Right Grant
- 2014-03-14 CN CN201480025303.7A patent/CN105189490A/zh active Pending
- 2014-03-14 MY MYPI2015702973A patent/MY181766A/en unknown
- 2014-03-14 CA CA2906691A patent/CA2906691A1/en not_active Abandoned
- 2014-03-14 UY UY0001035439A patent/UY35439A/es not_active Application Discontinuation
- 2014-03-14 EA EA201591706A patent/EA037527B1/ru unknown
- 2014-03-14 PT PT147188544T patent/PT2970250T/pt unknown
- 2014-03-14 ES ES14718854T patent/ES2872326T3/es active Active
- 2014-03-14 AU AU2014240028A patent/AU2014240028B2/en active Active
- 2014-03-14 US US14/776,432 patent/US9518049B2/en active Active
- 2014-03-14 RS RS20210607A patent/RS61852B1/sr unknown
- 2014-03-14 SG SG11201507054YA patent/SG11201507054YA/en unknown
- 2014-03-14 MA MA38488A patent/MA38488A1/fr unknown
- 2014-03-14 MX MX2015012295A patent/MX370178B/es active IP Right Grant
- 2014-03-14 DK DK14718854.4T patent/DK2970250T3/da active
- 2014-03-14 JP JP2016502330A patent/JP6438455B2/ja active Active
- 2014-03-14 KR KR1020157028855A patent/KR102302064B1/ko active IP Right Grant
- 2014-03-14 PL PL14718854T patent/PL2970250T3/pl unknown
- 2014-03-14 EP EP14718854.4A patent/EP2970250B1/en active Active
- 2014-03-14 TW TW103109465A patent/TWI713438B/zh active
- 2014-03-14 HU HUE14718854A patent/HUE054349T2/hu unknown
- 2014-03-14 WO PCT/US2014/027081 patent/WO2014152215A1/en active Application Filing
- 2014-03-14 LT LTEP14718854.4T patent/LT2970250T/lt unknown
- 2014-03-14 SI SI201431813T patent/SI2970250T1/sl unknown
-
2015
- 2015-09-06 IL IL241229A patent/IL241229B/en active IP Right Grant
- 2015-09-07 ZA ZA2015/06602A patent/ZA201506602B/en unknown
- 2015-09-09 PH PH12015502021A patent/PH12015502021A1/en unknown
- 2015-09-13 SA SA515361078A patent/SA515361078B1/ar unknown
- 2015-09-14 CL CL2015002701A patent/CL2015002701A1/es unknown
- 2015-09-15 TN TN2015000427A patent/TN2015000427A1/en unknown
-
2016
- 2016-03-10 HK HK16102769.7A patent/HK1214821A1/zh unknown
-
2021
- 2021-05-04 HR HRP20210692TT patent/HRP20210692T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210692T1 (hr) | Oblici soli (s)-kinuklidin-3-il (2-(2-(4-fluorfenil)tiazol-4-il)propan-2-il)karbamata | |
| HRP20200226T1 (hr) | Inhibitor glukozilceramid sintaze | |
| HRP20161038T1 (hr) | Genz 112638 za liječenje gaucherove ili fabrijeve bolesti u kombiniranoj terapiji | |
| HRP20210398T1 (hr) | Režimi doziranja za liječenje pompeove bolesti | |
| NZ602510A (en) | Treatment of lupus nephritis using laquinimod | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| JP2016106150A5 (hr) | ||
| HRP20160327T1 (hr) | Čvrsti dozirni oblici fentanila s poboljšanom bukalnom apsorpcijom | |
| BR112014024833A8 (pt) | Produto farmacêutico veterinário mastigável macio, processo para a fabricação de um produto, uso de ácido pamóico ou um sal farmaceuticamente aceitável do mesmo, uso de um produto farmacêutico veterinário mastigável macio, e, composição farmacêutica veterinária mastigável macia. | |
| CY1112772T1 (el) | Μεθοδος για την τροποποιηση κρυσταλλικου σχηματισμου φαρμακου του αλατος μυκοφαινολικου νατριου | |
| JP2015519329A5 (hr) | ||
| NO20065078L (no) | Inhaleringspulver formuleringer inneholdende enantiomerisk rene beta-agonister. | |
| NZ604983A (en) | Dry powder formulation comprising an antimuscarinic drug | |
| HRP20171515T1 (hr) | Spojevi fenoksietilpiperidina | |
| ES2716133T3 (es) | Composiciones farmacéuticas y usos dirigidos a trastornos de almacenamiento lisosomal | |
| HRP20171742T4 (hr) | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom | |
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| HRP20161389T1 (hr) | Derivati pantotenata namijenjeni liječenju neuroloških poremećaja | |
| HRP20140896T1 (hr) | (-)-stereoizomer 2,6-di-sec-butilfenola i njegovi analozi za poticanje antiemetskog uäśinka, lijeäśenje muäśnine i povraä†anja, te lijeäśenje migrene | |
| JP2014504636A5 (hr) | ||
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| EA201591415A1 (ru) | Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии | |
| WO2012063005A3 (fr) | Composition pharmaceutique et forme galenique a base de dronedarone et son procede de preparation | |
| TW200800977A (en) | A new salt | |
| IN2014MN01806A (hr) |